Orphazyme to showcase data on arimoclomol in Niemann-Pick disease Type C during the 2021 Annual WORLDSymposium™
Feb 4, 2021
Orphazyme US (ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced plans to present a series of data on its investigational drug arimoclomol during the 17th Annual WORLDSymposium Scientific Meeting, to be held virtually on February 8-12, 2021.
Orphazyme to showcase data on arimoclomol in niemann
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Feb 1, 2021
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Read moreCapital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Feb 1, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the vesting and exercise of Matching Shares. A total of 170,131 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Matching Share of DKK 1.
Capital increase of 170 131 shares in orphazyme
Read moreMajor shareholder announcement
Jan 18, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S, that as of January 15, 2021, Danske Bank A/S holds a total of 34,697,703 shares in the Company, corresponding to 3.49% of the Company’s share capital and that Danske Bank A/S as of January 15, 2021 controls 4.95% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Jan 4, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces Anders Vadsholt, Chief Financial Officer of Orphazyme, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, which is being held virtually from January 6-8 and 11-14, 2021.
Orphazyme to take part in panel discussion
Read moreOrphazyme provides regulatory update on arimoclomol for NPC
Dec 26, 2020
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announced today the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC) by a standard extension period of three months. This extension is necessary for the FDA to complete its review. The updated Prescription Drug User Fee Act (PDUFA) target action date is June 17, 2021.
Read moreKim Stratton, CEO, resigns from Orphazyme
Dec 10, 2020
Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a dialogue initiated by the board of directors. Orphazyme will initiate a search for a new CEO immediately. Meanwhile, in order to ensure continuity going forward, Georges Gemayel, Chairman of the Board of Directors, will temporarily assist the executive team of Orphazyme with the day-to-day operations until a new CEO is appointed.
Kim Stratton ceo resigns from Orphazyme
Read moreFinancial calendar 2021
Dec 9, 2020
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the company expects to publish financial reports according to the following schedule.
Read moreOrphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization
Dec 2, 2020
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced it has established its U.S. headquarters in Chicago.
Orphazyme establishes u s headquarters in chicago
Read moreOrphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C
Nov 9, 2020
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its investigational product candidate arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme submits european maa for arimoclomol
Read more